Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes
Jithma P. Abeykoon(Mayo Clinic), Prashant Kapoor, David Dingli, Sameer A. Parikh(Mayo Clinic), Morie A. Gertz(Medical University of South Carolina), Rebecca L. King(Mayo Clinic in Arizona), Nelson Leung(WinnMed), Robert A. Kyle(Mayo Clinic), Carrie A. Thompson(Mayo Clinic), Thomas M. Habermann(Mayo Clinic in Arizona), Shaji Kumar(Mayo Clinic), Ronald S. Go(Mayo Clinic), Anne J. Novak(Mayo Clinic), Michelle K. Manske(Mayo Clinic in Arizona), Rahma Warsame, Stephen M. Ansell(Mayo Clinic), S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), David J. Inwards(Mayo Clinic), Patricia T. Greipp(Mayo Clinic), Saurabh Zanwar(Mayo Clinic), Martha Q. Lacy(Mayo Clinic), Angela Dispenzieri(Mayo Clinic), Eli Muchtar(Mayo Clinic), Thomas E. Witzig(WinnMed)
Cited by 50
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k